Header

UZH-Logo

Maintenance Infos

Use of neuroenhancement drugs: prevalence, frequency and use expectations in Switzerland


Deline, Stéphane; Baggio, Stéphanie; Studer, Joseph; N'Goran, Alexandra A; Dupuis, Marc; Henchoz, Yves; Mohler-Kuo, Meichun; Daeppen, Jean-Bernard; Gmel, Gerhard (2014). Use of neuroenhancement drugs: prevalence, frequency and use expectations in Switzerland. International Journal of Environmental Research and Public Health, 11(3):3032-3045.

Abstract

OBJECTIVE: The present study investigates the use expectations, prevalence and frequency of neuroenhancement drug (ND) use among the Swiss male population, separating college students from others.
METHODS: Young Swiss men were invited to participate in the Cohort Study on Substance Use Risk Factors. A total of 5,967 participants responded to questions on six types of NDs (wakefulness medication, antidepressants, Alzheimer's disease medication, Parkinson's disease medication, attention deficit-hyperactivity disorder (ADHD) medication, and beta-blockers). The frequency of use depending on five expectations (to enhance wakefulness, attention, memory, concentration and stress reduction) was analyzed for a twelve-month period.
RESULTS: (1) About 3% of the sample indicated use of at least one ND; (2) ADHD medication was the most prevalent; (3) The type of ND preferred differed depending on academic status (4). Quantitatively, over the year, college student users used ND much less frequently than other users.
CONCLUSIONS: Prevalence of ND use is low in Switzerland relative to other countries such as the United States. Patterns of ND use differed depending on academic status, suggesting that while college student ND users tended to do so rarely (probably to enhance cognitive abilities for exams), non-college male users used other NDs more frequently (probably to "get high").

Abstract

OBJECTIVE: The present study investigates the use expectations, prevalence and frequency of neuroenhancement drug (ND) use among the Swiss male population, separating college students from others.
METHODS: Young Swiss men were invited to participate in the Cohort Study on Substance Use Risk Factors. A total of 5,967 participants responded to questions on six types of NDs (wakefulness medication, antidepressants, Alzheimer's disease medication, Parkinson's disease medication, attention deficit-hyperactivity disorder (ADHD) medication, and beta-blockers). The frequency of use depending on five expectations (to enhance wakefulness, attention, memory, concentration and stress reduction) was analyzed for a twelve-month period.
RESULTS: (1) About 3% of the sample indicated use of at least one ND; (2) ADHD medication was the most prevalent; (3) The type of ND preferred differed depending on academic status (4). Quantitatively, over the year, college student users used ND much less frequently than other users.
CONCLUSIONS: Prevalence of ND use is low in Switzerland relative to other countries such as the United States. Patterns of ND use differed depending on academic status, suggesting that while college student ND users tended to do so rarely (probably to enhance cognitive abilities for exams), non-college male users used other NDs more frequently (probably to "get high").

Statistics

Citations

7 citations in Web of Science®
9 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

53 downloads since deposited on 13 Feb 2015
20 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:March 2014
Deposited On:13 Feb 2015 12:06
Last Modified:21 Nov 2017 17:45
Publisher:MDPI Publishing
ISSN:1660-4601
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.3390/ijerph110303032
PubMed ID:24625621

Download

Download PDF  'Use of neuroenhancement drugs: prevalence, frequency and use expectations in Switzerland'.
Preview
Content: Published Version
Filetype: PDF
Size: 393kB
View at publisher